您的购物车当前为空
ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes.
ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 50 mg | 待询 | 待询 | |
| 100 mg | 待询 | 待询 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
凭借在化合物合成方面的丰富经验,我们可以根据您的研究需求为该产品提供快速定制合成服务。
| 产品描述 | ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes. |
| 体外活性 | ATWLPPR Peptide TFA inhibits VEGF165 binding to NRP-1 by 82% at 100 μM [1]. |
| 体内活性 | ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes. ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF, and ICAM-1) in the retina [2]. |
| 分子量 | 954 |
| 分子式 | C42H62F3N11O11 |
| Smiles | O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)[C@H](C)N.OC(C(F)(F)F)=O |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | ||||||||||||||||||||||||||||||
| 溶解度信息 | H2O: 50 mg/mL (52.41 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
H2O
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | |||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多